Legend Biotech taps Novartis veteran as CEO amid CAR-T rivalry
Legend Biotech has appointed Ingrid Zhang, a former Novartis executive, as its new chief executive. The leadership change comes as the company faces intensifying competition for its CAR-T therapy Carvykti, with shares having dropped by half. Vertex Pharmaceuticals also announced several strategic moves, though details were not provided.
Legend Biotech has named Ingrid Zhang, previously an executive at Novartis, to lead the company as chief executive. The appointment arrives during a turbulent period for the firm, whose stock value has fallen roughly fifty percent amid growing pressure in the marketplace for its cancer cell therapy, Carvykti. The treatment faces mounting rivalry from other developers in the CAR-T space.
Separately, Vertex Pharmaceuticals disclosed a series of strategic initiatives, though the specifics of those moves were not made public. The leadership transition at Legend signals a shift in direction as the company navigates competitive headwinds in the oncology sector.
This leadership change could influence patient access to CAR-T therapies if competitive dynamics alter pricing or availability. Investors may face continued volatility as the company recalibrates strategy under new management. The broader biotech sector could see shifts in partnership patterns, potentially affecting how quickly innovative cancer treatments reach clinics. Patients with blood cancers may benefit indirectly if intensified competition spurs improvements in treatment efficacy or delivery, though such outcomes remain uncertain.